Skip to main content

SCPH

Stock
Health Care
Biotechnology

Performance overview

SCPH Price
Price Chart

Forward-looking statistics

Beta
0.88
Risk
58.12%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.

Company info

SectorHealth Care
IndustryBiotechnology
Employees92
Market cap$135.2M

Fundamentals

Enterprise value$195.6M
Revenue$42.0M
Revenue per employee
Profit margin-216.24%
Debt to equity-10.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.92
Dividend per share
Revenue per share$0.87
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth+3.0
Credit+5.6
Liquidity-3.0
Inflation-0.3
Commodities-0.5
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio-5.44
Price to sales4.99
P/E Ratio-5.44
Enterprise Value to Revenue4.66
Price to book-40.83

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.36 per share a year ago.

Zacks Investment Research (May 14, 2025)
scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients

scPharmaceuticals Inc (NASDAQ: SCPH) announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure.  Patients were treated with the Company's investigational Furoscix, post-discharge from the emergency department, compared to a historical comparator group treated with intravenous furosemide in the inpatient hospital setting.

Benzinga (July 14, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free